A director of Enliven Therapeutics sold 10,000 shares in open-market transactions on June 5, 2026, for total proceeds of $345,000. The filing is routine insider-transaction disclosure and does not, by itself, indicate a material change in the company’s fundamentals or outlook.
A director of Enliven Therapeutics sold 10,000 shares in open-market transactions on June 5, 2026, for total proceeds of $345,000. The filing is routine insider-transaction disclosure and does not, by itself, indicate a material change in the company’s fundamentals or outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
-0.05
Ticker Sentiment
